Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial.

Kimura S, Imagawa J, Murai K, Hino M, Kitawaki T, Okada M, Tanaka H, Shindo M, Kumagai T, Ikezoe T, Uoshima N, Sato T, Watanabe R, Kowata S, Hayakawa M, Hosoki T, Ikeda K, Kobayashi T, Kakinoki Y, Nishimoto T, Takezako N, Shibayama H, Takaori-Kondo A, Nakamae H, Kawaguchi A, Ureshino H, Sakamoto J, Ishida Y, DADI Trial Group

Open source

DOI: 10.1016/s2352-3026(19)30235-2
Published: 2020 Mar
Container: The Lancet. Haematology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2352-3026-19-30235-2,
  title = {Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial.},
  author = {Kimura S and Imagawa J and Murai K and Hino M and Kitawaki T and Okada M and Tanaka H and Shindo M and Kumagai T and Ikezoe T and Uoshima N and Sato T and Watanabe R and Kowata S and Hayakawa M and Hosoki T and Ikeda K and Kobayashi T and Kakinoki Y and Nishimoto T and Takezako N and Shibayama H and Takaori-Kondo A and Nakamae H and Kawaguchi A and Ureshino H and Sakamoto J and Ishida Y and DADI Trial Group},
  year = {2020},
  journal = {The Lancet. Haematology},
  doi = {10.1016/s2352-3026(19)30235-2},
  url = {https://doi.org/10.1016/s2352-3026(19)30235-2}
}

RIS

TY  - JOUR
TI  - Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial.
AU  - Kimura S
AU  - Imagawa J
AU  - Murai K
AU  - Hino M
AU  - Kitawaki T
AU  - Okada M
AU  - Tanaka H
AU  - Shindo M
AU  - Kumagai T
AU  - Ikezoe T
AU  - Uoshima N
AU  - Sato T
AU  - Watanabe R
AU  - Kowata S
AU  - Hayakawa M
AU  - Hosoki T
AU  - Ikeda K
AU  - Kobayashi T
AU  - Kakinoki Y
AU  - Nishimoto T
AU  - Takezako N
AU  - Shibayama H
AU  - Takaori-Kondo A
AU  - Nakamae H
AU  - Kawaguchi A
AU  - Ureshino H
AU  - Sakamoto J
AU  - Ishida Y
AU  - DADI Trial Group
PY  - 2020
JO  - The Lancet. Haematology
DO  - 10.1016/s2352-3026(19)30235-2
UR  - https://doi.org/10.1016/s2352-3026(19)30235-2
ER  -

APA

S, K., J, I., K, M., M, H., T, K., M, O., H, T., M, S., T, K., T, I., N, U., T, S., R, W., S, K., M, H., T, H., K, I., T, K., Y, K., T, N., N, T., H, S., A, T., H, N., A, K., H, U., J, S., Y, I., & Group, D. T. (2020). Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial.. The Lancet. Haematology. https://doi.org/10.1016/s2352-3026(19)30235-2

Source records

pubmed · retrieved 2026-09-25T22:11:00.314Z